company background image
AGEN logo

Agenus NasdaqCM:AGEN Stock Report

Last Price

US$4.65

Market Cap

US$98.2m

7D

-4.1%

1Y

-78.3%

Updated

09 Oct, 2024

Data

Company Financials +

AGEN Stock Overview

A clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally.

AGEN fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Agenus Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Agenus
Historical stock prices
Current Share PriceUS$4.65
52 Week HighUS$23.20
52 Week LowUS$4.41
Beta1.36
11 Month Change-9.36%
3 Month Change-69.79%
1 Year Change-78.27%
33 Year Change-95.69%
5 Year Change-91.06%
Change since IPO-99.94%

Recent News & Updates

Agenus: Novel Drugs That Just Are Not Novel

Jul 24

Recent updates

Agenus: Novel Drugs That Just Are Not Novel

Jul 24

There's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise

May 21
There's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise

Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results

May 09
Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results

Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet

Mar 29
Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet

Agenus: 2024 May Finally Be The Year For A Major Turnaround

Jan 18

Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet

Dec 22
Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet

News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts

Nov 09
News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts

A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)

Oct 04
A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)

Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts

May 10
Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts

VBI Vaccines, Agenus to examine VBI-1901 + balstilimab combo for glioblastoma

Oct 12

Agenus New Trials Set It Up For The Long Haul

Sep 27

Agenus: It's Always Tomorrow

Sep 16

Agenus GAAP EPS of -$0.17, revenue of $20.93M

Aug 09

Agenus: Successfully Pulled Itself Away From Disaster

Jul 04

Agenus: Not Quite Enough

Apr 19

Auditors Have Doubts About Agenus (NASDAQ:AGEN)

Mar 06
Auditors Have Doubts About Agenus (NASDAQ:AGEN)

Agenus: Making Another Effort With The FDA

Jan 25

Agenus Inc.'s Imminent 1181/Bal Data Release And MiNK IPO Should Lead To Enormous Valuation Gains

Aug 25

Agenus Multiple Value-Adding Events Ahead

Aug 18

Party Time: Brokers Just Made Major Increases To Their Agenus Inc. (NASDAQ:AGEN) Earnings Forecasts

Aug 11
Party Time: Brokers Just Made Major Increases To Their Agenus Inc. (NASDAQ:AGEN) Earnings Forecasts

Shareholder Returns

AGENUS BiotechsUS Market
7D-4.1%-1.1%0.6%
1Y-78.3%17.1%30.3%

Return vs Industry: AGEN underperformed the US Biotechs industry which returned 17.1% over the past year.

Return vs Market: AGEN underperformed the US Market which returned 30.3% over the past year.

Price Volatility

Is AGEN's price volatile compared to industry and market?
AGEN volatility
AGEN Average Weekly Movement20.8%
Biotechs Industry Average Movement10.0%
Market Average Movement6.4%
10% most volatile stocks in US Market15.0%
10% least volatile stocks in US Market3.2%

Stable Share Price: AGEN's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: AGEN's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1994389Garo Armenwww.agenusbio.com

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant.

Agenus Inc. Fundamentals Summary

How do Agenus's earnings and revenue compare to its market cap?
AGEN fundamental statistics
Market capUS$98.15m
Earnings (TTM)-US$223.67m
Revenue (TTM)US$159.63m

0.6x

P/S Ratio

-0.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AGEN income statement (TTM)
RevenueUS$159.63m
Cost of RevenueUS$199.65m
Gross Profit-US$40.02m
Other ExpensesUS$183.65m
Earnings-US$223.67m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-10.37
Gross Margin-25.07%
Net Profit Margin-140.12%
Debt/Equity Ratio-6.1%

How did AGEN perform over the long term?

See historical performance and comparison